Shangmei Co., Ltd. (Stock code: (02145.HK) and Kaituoyao Pharmaceutical enter into a strategic partnership to promote the commercialization of the whitening and spot-removal raw material KT-939.

NightAirdropper · 2026-03-20T17:24:34+00:00

Shang Mei Co., Ltd. has signed a strategic cooperation agreement with Suzhou Kaituozhi, a wholly-owned subsidiary of Pioneer Pharmaceuticals, aiming to rapidly commercialize the whitening and spot-removal ingredient KT-939, advance its registration and related product development, and strengthen the company's influence and leadership position in the cosmetics market.

NightAirdropper

2026-03-20 17:24:34

Abstract generation in progress

Gelonghui, March 17 — Shangmei Holdings (02145.HK) announced that recently the company and KaiTuo Pharmaceuticals Limited (a company listed on the Hong Kong Stock Exchange with stock code: 9939, “KaiTuo Pharmaceuticals”) through its wholly owned subsidiary Suzhou KaiTuo Pharmaceuticals Co., Ltd. (“Suzhou KaiTuo”) signed a strategic cooperation framework agreement with exclusive terms in the cosmetics field, related to the rapid commercialization of the whitening and spot-removing functional cosmetic raw material KT-939.

Under the framework agreement, the company and Suzhou KaiTuo will collaboratively promote the registration of KT-939 in China as a new cosmetic ingredient and the registration of cosmetic products centered on KT-939 with exclusive terms in the cosmetics field. They will also jointly develop and customize efficacy raw materials, aiming to create a highly influential “the strongest domestically produced whitening product” based on KT-939.

The company plans to leverage the development, registration, and application of KT-939 functional cosmetic raw materials to further diversify its product portfolio, enhance its scientific research barrier in cutting-edge cosmetic raw materials and product efficacy, and strengthen its leadership position in the whitening and spot-removing functional cosmetic market.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.